CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

Last updated: February 26, 2026
Sponsor: Duke University
Overall Status: Terminated

Phase

2

Condition

Diabetes Mellitus, Type 2

Treatment

Placebo

Empagliflozin10Mg Tab

Clinical Study ID

NCT04906213
Pro00107752
  • Ages > 18
  • All Genders

Study Summary

CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Equal to or greater than 12 months and up tp 60 months post kidney transplant

  2. Estimated glomerular filtration rate (eGFR) equal to or greater than 30ml/min/1.73msquared at screening

  3. Standard immunosuppression, including calcineurin inhibitor, Mycophenolate Mofetilor Sodium and a glucocorticoid

  4. Able to provide written consent -

Exclusion

Exclusion Criteria:

  1. Type I diabetes

  2. Any other solid organ transplant

  3. Hemoglobin A1c greater than 12 %

  4. SGLT2i use at the time of enrollment

  5. Prior SGLT2i allergy or intolerance

  6. Pregnant or nursing at the time of enrollment

  7. History of antibody medicated rejection (AMR) or a Banff score greater than 2B foracute cellular rejection (ACR)

  8. Active anticoagulant use other than aspirin 81 mg for primary prevention ofcardiovascular disease

  9. Known positive donor-specific antibodies prior to enrollment

  10. Uncircumcised men

  11. Greater than 2 urinary tract infections (UTI) over the 12 months prior to enrollment

  12. Any genital infections over the 12 months prior to enrollment -

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
July 25, 2022
Estimated Completion Date:
January 22, 2026

Study Description

A screening visit will occur at which time an informed consent will be obtained, and eligibility determined. Women of childbearing potential will have a serum pregnancy test performed. This will be followed by a baseline visit. A renal biopsy and a 3D echocardiogram will be performed. At the next visit randomization will be performed and the subjects will receive their study medication, either empagliflozin or a placebo. Following the randomization visit the subject will return every 3 months (visits 2-7) for a total of 6 visits spanning 18 months. At each visit vital signs and weight will be taken. Other procedures include labs drawn for hematology, basic chemistry, coagulation, Glycated hemoglobin and serum insulin. A 3 D echocardiogram is repeated on Visits 4 and 6. A renal biopsy is repeated on Visit 3.

Connect with a study center

  • Duke University Medical Center

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Duke University Medical Center

    Durham 4464368, North Carolina 4482348 27710
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.